

Status of Dialogue with Shareholders and Investors Fiscal 2023 Results

June 28, 2024

KISSEI PHARMACEUTICAL CO., LTD.

Disclaimer: This document is an English translation of the original document in Japanese and has been prepared solely for reference purposes. In the event of any discrepancy between this English translation and the original in Japanese, the original shall prevail in all respects.

Status of Dialogues with Shareholders and Investors (Fiscal 2023)

Main People Involved in Dialogues with Shareholders

• The Public Relations Department is in charge of handling shareholder dialogues appropriately in collaboration with the president and representative Director, as well as with directors and departments in charge of such dialogues.

Overview of Dialogues with Shareholders

• Financial briefings for analysts

May 2022: Financial briefing for the fiscal year ended March 31, 2023

November 2023: Financial briefing for the second quarter of fiscal 2023

People-in-charge:

President

Managing director and department manager of Corporate Finance and Management Department Senior corporate officer and division director of the Clinical Development Division

Status of feedback to management and the Board of Directors regarding shareholder opinions and concerns identified through dialogue

- We hold financial briefings, disclose information via our corporate website, and conduct other activities to deepen shareholders' understanding of our management strategy and business environment.
- Opinions expressed through these activities and dialogues with shareholders are shared with the Board of Directors as appropriate and utilized when reviewing management strategies.
- Considering holding R&D meetings based on opinions expressed in dialogues with shareholders, etc.

• IR Meetings by Category (out of 66 total)



